Saruparib recapitulates PARP-BRCA synthetic lethality with PARP1-trapping properties limiting its cytotoxicity
The original concept of PARP synthetic lethality proposes that loss of poly(ADP-ribose) polymerase (PARP) activity selectively kills homologous recombination (HR)-deficient cells. However, clinically approved PARP1/2 inhibitors (PARPis) are used at exposures exceeding those required for catalytic inhibition. At these doses, PARP trapping is cytotoxic to HR-proficient cells and limits the therapeutic window in HR-deficient cancers. Saruparib has been developed as a PARP1-selective inhibitor to reduce PARP2-associated toxicity; yet its PARP1-trapping properties remain incompletely characterized. Here, we show that saruparib exhibits trapping properties distinct from those of conventional PARPis. It causes minimal cytotoxicity in HR-proficient cells and remains minimally toxic in XRCC1-deficient cells, which are highly sensitive to trapping-associated cytotoxicity induced by conventional PARPis. Although methyl methanesulfonate, which induces extensive base damage, increases saruparib-induced PARP1 trapping and cytotoxicity, the overall trapping-associated cytotoxic response is weaker than that induced by olaparib and shows little further dose-dependent increase once catalytic PARP1 inhibition is achieved. Biochemical measurements demonstrated that PARP1-DNA complexes formed in the presence of saruparib are less stable than those in the presence of olaparib or talazoparib. Notably, saruparib potently kills BRCA1-, BRCA2-, and PALB2-deficient cells at concentrations sufficient for near-maximal catalytic inhibition, without a corresponding increase in cytotoxicity in HR-proficient cells. Thus, saruparib combines potent HR-deficient-selective cytotoxicity with limited PARP1 trapping and associated toxicity. Consequently, saruparib closely recapitulates the PARP-BRCA synthetic lethality while sparing HR-proficient cells, providing a mechanistic framework for its rational clinical use.
Authors
- Shingo Dan (ORCID: https://orcid.org/0000-0002-0022-2725)
- Sho Isoyama (ORCID: https://orcid.org/0000-0001-6751-1233)
- Kenjiro Sawada (ORCID: https://orcid.org/0000-0001-7384-2581)
- Yves Pommier
- Erina Kusakabe
- Kaho Utsunomiya
- Ryo Kamata (ORCID: https://orcid.org/0000-0001-6970-9657)
- Hiroyuki Sasanuma (ORCID: https://orcid.org/0000-0003-2824-4499)
- Junko Murai (ORCID: https://orcid.org/0000-0003-2023-6160)
- Hiroshi Onji (ORCID: https://orcid.org/0000-0001-5778-0149)
- Takashi Sugiyama (ORCID: https://orcid.org/0000-0002-3715-0075)
- Tomohiro Iguchi
- Koji Hirota
- Shiho Nakano
Institutions
- National Institutes of Health (US)
- Tokyo Metropolitan Institute of Medical Science (JP)
- Japanese Foundation For Cancer Research (JP)
- Ehime University (JP)
- Premier Institute for Advanced Studies, Ehime University (JP)
- Proteo-Science Center, Ehime University (JP)
- Tokyo Metropolitan University (JP)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.64898/2026.11.17.767429
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- preprint